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Abstract

Purpose: Using a retrospective analysis of treatment plans submitted from multiple institutions
accruing patients to the RTOG #0236 non-small cell SBRT protocol, this study determines the dose
prescription and critical structure constraints for future SBRT lung protocols that mandate density
corrected dose calculations.
Method and Materials: A subset of twenty patients from four institutions participating in the
0236 protocol and using superposition/convolution algorithms are compared. The 0236
protocol required a prescription dose of 60 Gy delivered in three fractions to cover 95% of the
PTV volume. Additional requirements were specified for target dose heterogeneity and dose
to normal tissue/structures. The protocol required each site to plan the patient’s treatment
using unit density, and another plan with the same monitor units and applying density
corrections was also submitted. These plans have been compared to determine dose
differences. A two-sided paired student’s t-tests were used to evaluate these differences.

Results: With heterogeneity corrections applied, the volume of PTV receiving 60 Gy or more
(V60) decreased on average 10.1% (SE=2.7%) from 95% (p=0.001). Maximum dose to any
point 2 cm or greater away from the PTV increased from 35.2 Gy (SE =1.7 Gy) to 38.5
(SE=2.2 Gy).

Conclusions: Statistically significant dose differences were found with heterogeneity
corrections. The information provided in this study is currently being used for designing future
heterogeneity corrected RTOG SBRT lung protocols to match the true dose delivered for 0236.
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Purpose:
Lung cancer remains the most frequent cause of cancer death in both men and women in
North America. Lung cancer accounts for approximately 15% of all cancers diagnosed but 2631% of all cancer deaths.

1

These statistics have been more or less stable over the years

2-4

.

Seventy-five percent of patients with bronchogenic carcinoma will be diagnosed with non-small
cell lung cancer (NSCLC). Approximately 15-20% of NSCLC patients present with early or
localized disease.

5

The number of patients diagnosed with stage I NSCLC is expected to rise

significantly in the next several decades due to widespread screening with spiral CT scanning.6
Surgical resection of stage I (T1-2, NO) NSCLC results in five-year survival rates of
approximately 60-70%,

7-9

and remains the treatment of choice for this population.

Unfortunately, some patients with early stage NSCLC are unable to tolerate the rigors of
surgery or the post-operative recovery period due to lack of adequate respiratory reserve,
cardiac dysfunction, diabetes mellitus, vascular disease, general frailty, or other co-morbidities.
Primary radiotherapy for early stage non-small lung cancer is considered reasonable nonsurgical therapy for such patients, with reported five-year survival rates ranging from 10-30%.
10-16

The standard approach involves giving approximately 45-66 Gy total dose in 1.8-2.0 Gy

fractions. This regimen has been established based on early experience of treatment with
radiation and has been justified by widely accepted models of radiobiological effects of x rays
on human tissue. Early evaluations of radiation therapy showed that the delivery of large
radiation field treatments was leading to unacceptably high toxicities17 . However, early
radiotherapy delivery techniques were limited in the inability to decrease exposure of normal
tissues due to low beam energies utilized. These treatments suffered also from large targeting

uncertainties caused by the unavailability of modern imaging techniques and less than ideal
representations of the dose distribution inside the patient anatomy18 .
Newer techniques such as 3-D conformal radiotherapy (3D-CRT) have been proven to allow
significant dose escalation of fractionated radiotherapy in locally advanced lung cancer in a
Radiation Therapy Oncology Group (RTOG) trial.

19

SBRT, which utilizes elements of 3-DCRT

in addition to stereotactic localization, incorporates a variety of systems for decreasing the
effects of lung and other organ motion that would otherwise translate into target motion. These
systems allow even more dramatic reduction of treatment volumes facilitating hypofractionation
with markedly increased daily doses and significantly reduced overall treatment time. RTOG
protocol 0236 is designed to determine if radiotherapy involving high biological dose with
limited treatment volume (using SBRT techniques) achieves acceptable local control (i.e., ≥
80%) in frail patients with medically inoperable early stage non-small cell lung cancer.
Dose calculation with/without tissue density corrections are reported to have dramatic
deviations for radiotherapy planning especially in the thoracic region

20-23

. The differences

exist for the dose to the isocentric point, and for the dose distributions, including target
coverage and normal structure sparing. Many centers participating in RTOG trials for lung
cancer did not have access to more accurate dose calculation techniques such as
superposition/convolution algorithms or Monte Carlo method in 2000 and 2001 when RTOG
0236 was being designed. In addition, phantom measurements and calculations reported in
the literature showed that reasonable accuracy and more importantly consistency from center
to center could be achieved by simply not using the vendor’s heterogeneity correction
algorithm

24

. It was therefore decided not to allow tissue heterogeneity correction for

calculating monitor unit settings for RTOG 0236

25

. As required by the protocol, all dose

planning and calculation of monitor units for actual treatment were performed with all tissues
assuming unit (water) density. However, in an effort to ultimately better understand these
effects for improving future protocols, each plan was also calculated with software vendor
supplied heterogeneity corrections and submitted for QA purposes. The computation using
heterogeneity corrections had beam weights manipulated such that the number of monitor
units was the same for each beam between the plans.
This study evaluates those treatment plans with and without heterogeneity corrections
submitted from multiple institutions accruing patients to RTOG protocol 0236 and reports on
the effect of tissue density correction on the various dose objectives specified in the protocol.

Method and Materials:
This analysis was limited to those institutions which used treatment planning algorithms that
approximate changes for lateral electron transport in contrast with those based on equivalent
path length correction only. Studies have found that, if commissioned appropriately, models
that consider changes in lateral electron transport tend to predict doses more accurately when
compared with Monte Carlo calculations and/or actual dose measurements

26-30

. The planning

systems and heterogeneity correction algorithms meeting these criteria were Pinnacle (Royal
Philips Electronics of the Netherlands) collapsed cone and CMS/XIO (The Elekta Group)
superposition/convolution algorithms.
The system from Pinnacle is based on a fluence model using collapsed cone convolution, in
which the kernel is not separated into primary and scatter components during convolution 31-34 .
The XiO system from CMS has two fluence dose calculation models, a Fast Fourier Transform
(FFT) based convolution algorithm and a more exact multi-grid fast superposition method

35, 36

. The FFT convolution is performed in the frequency domain with the kernel from Mackie et al
37

. For the multi-grid superposition method, during integration the kernels which are now

represented in spherical coordinates are modified according to density changes in the
irradiated medium with the use of a varying resolution for the calculation grid depending on
potential dose gradients, e.g., at high density gradients and at beam edges a finer grid is used.
A brief summary of the treatment planning requirements for the protocol 38 is given below.
•

Three-dimensional coplanar or non-coplanar beam arrangements will be custom designed

for each case to deliver highly conformal prescription dose distributions. Non-opposing, noncoplanar beams are preferable. Seven or more beams of radiation will be used with roughly
equal weighting. A typical beam arrangement is shown in Figure 1.
•

Field aperture size and shape should correspond nearly identically to the beam’s-eye view

(BEV) projection of the PTV (i.e. no additional “margin” beyond the PTV)
•

All tissues within the body, including lung, were assumed to have unit (water) for planning

calculation. However, each plan was also calculated, using the same monitor units as the unit
density plan, with heterogeneity corrections enabled. The protocol required the submission of
the corrected plan in digital form for QA purposes.
•

The plan should be normalized to a defined point corresponding closely to the center of

mass of the PTV (called the COMPTV).
•

The prescribed dose of 60 Gy should cover 95% of the PTV.

•

A dose that is 90% of the prescribed dose (54 Gy) should cover at least 99% of the PTV.

•

Under the above conditions, the maximum dose within the target should fall between 67

and 100 Gy.

•

Any dose greater than 105% of the prescription dose (63 Gy) should occur primarily within

the PTV. The cumulative volume of all tissue outside of the PTV receiving a dose greater than
105% of prescription dose (63 Gy) should be no more than 15% of the PTV.
•

Conformality of PTV coverage for this protocol is judged by the following constraints:

o The ratio of the volume of the prescription isodose to the volume of the PTV is to be no
more than 1.4 (Table 1). This criterion will not be required in treating very small tumors (< 2.5
cm axial GTV dimension or < 1.5 cm cranio-caudal GTV dimension).
o The falloff gradient beyond the PTV must be rapid in all directions and meet the following
criterion: The maximum total dose in Gy to any point 2 cm or greater away from the PTV must
be less than the number given in the column titled “maximum dose 2 cm from the PTV” in
Table 1. This table only lists unacceptable major deviations.
o The ratio of the volume within the isodose surface corresponding to a dose of 50% of the
prescription dose (30 Gy) to the volume of the PTV must be no greater than the R50% value
given in Table 1.
•

The absolute maximum dose limits for critical structures are listed in Table 1 and Table 2.

The protocol requires that the treatment planning data (including CTs, structures, 3D dose
matrix, and plans) be exported from institution’s treatment planning systems and submitted to
the Image Guided Therapy QA Center. A Digital Data Integrity QA process was performed for
each dataset, which included making sure all protocol required items were present and intact,
that images, structures, and dose distributions were spatially registered, and that doses were
properly scaled.

Structures were assigned protocol-specified names and DVHs were

recalculated with consistent spatial sampling and dose bin width parameters for both

heterogeneity-corrected and uncorrected dose matrices. Dose-volume statistics were then
computed from these DVHs.

Statistical methods
Since there is a relationship for each patient between the dosimetric data with and without
heterogeneity corrections applied, changes in dosimetric data with heterogeneity corrections
must be analyzed for each patient. The difference between dosimetric data with and without
heterogeneity corrections was calculated by subtracting the non-corrected dose from the dose
using heterogeneity corrections. A two-sided paired student’s t-test was then applied to that
difference using the null hypothesis that the actual mean does not differ significantly from 0.

Results and discussions:
Fifty-nine patients were accrued to RTOG 023639 . Of these, 20 patients from 4 institutions
met the criteria set in the protocol for this analysis. The PTV volumes for the patients studied
ranged from 10.7- 117 cc (cm3), with mean and standard deviation (STD) of 45 cc and 28 cc
respectively (Figure 2). The number of beams used for the various treatment plans ranged
from 8 to 12. The number of beams used for each case is labeled in the same figure. One can
observe from the figure that there was no correlation between the PTV volume and number of
beams necessary to adequately treat the volume. The photon beam energy used was 6 MV.
Figure 3 shows the isodose distributions without (left) and with (right) heterogeneity correction
on the isocentric axial slice for one of the cases submitted. It can be observed that with
heterogeneity correction applied, the prescription isodose line contracts while the 50% isodose

line extends, which is reflected in the dose volume histogram for the PTV (Figure 4). The
percent volume receiving 60 Gy decreases from 95% to 60% in this case.
The statistical changes of the plans with vs. without heterogeneity corrections are described in
the following categories: isocenter dose, 95% of PTV volume dose coverage, 99% of PTV
volume dose coverage, conformality of PTV coverage, and dose to critical structures.
Isocenter dose:
Figure 5 shows the effect on the isocenter dose as heterogeneity corrections are applied using
the non-corrected monitor units.

Of the submitted plans with unit density applied, the

isocentric dose ranges from 66.3 Gy to 82.2 Gy (mean 70.1 Gy, standard error (SE) 0.9 Gy).
With heterogeneity corrections applied, the isocenter dose ranges from 71.3 Gy to 88.9 Gy
(mean 78.8 Gy, SE 1.1 Gy). Included in Figure 5 are also the ratios of isocentric dose with
heterogeneity corrections over those without. One observes that all the ratios are greater than
or equal to one, meaning an increase of isocentric doses for all these submitted cases. The
relative increases range between -0.1% and 22% (mean 12.5%, and SE 1.2%).
95% of PTV volume dose coverage:
The protocol requires that 95% of the target volume (PTV) be conformally covered by the
prescription isodose surface of 60 Gy with no heterogeneity correction applied. As shown in
Figure 6, the actual percentage of the PTV receiving the prescription dose of 60 Gy (%V60)
ranges from 89.6% - 98.8% (mean 95.8%, SE 0.5%). Deviations from the required 95% have
a minimum of -5.4% to a maximum of 3.8% (mean 0.8%, SE 0.5%). With heterogeneity
corrections applied (Figure 6), V60 deviation from 95% has a wider range, from -37.4% to 2.7%
(mean -10.1%, SE 2.7%). The mean difference ranges from -37.4% to 1.2% (mean -10.8%, SE
2.8%, p=0.001).

Considering the dose delivered to 95% of the PTV (D95) for the unit density calculations, values
ranged from 57.0 Gy to 63.5 Gy (mean 60.6 Gy, SE 0.3 Gy). With heterogeneity correction
applied, D95 extends to a wider range from 44.1 Gy to 64.2 Gy (mean 55.9, SE 1.1 Gy). The
per-patient difference ranges from -16.0 Gy to 0.7 Gy (mean -4.7 Gy, SE 1.0 Gy, p=0.0002).
99% of PTV volume dose coverage:
The protocol requires that the percent volume receiving 90% of the prescription dose (54 Gy)
be no less than 99%.

This requirement is met by almost all the plans (Figure 7), with a

minimum of 97.7% and a maximum 100% (mean 99.2%, SE 0.1%). For the heterogeneity
corrected plans, the deviation from 99% can be as much as -20.5%, with 4 cases deviating
more than 5% (Figure 7). The per-patient differences range from -20.% to 0.5% (mean -4.1%,
SE 1.3%, p=0.006). Similar results are seen in the dose to 99% of the volume (D99). This
parameter extends from a minimum of 49.8 Gy to a maximum 59.6 Gy (mean 55.1 Gy, SE 0.5
Gy) when unit density calculations are performed, and to a range of 38.4 Gy to 73 Gy (51.4 Gy,
SE 1.6 Gy) with heterogeneity correction. The per-patient difference ranges from -16.1 Gy to
14.2 Gy (mean -3.7 Gy, SE 1.4 Gy, p=0.02). The D90 for non-corrected planning has a range of
59.8 Gy to 67.7 Gy (mean 62.7 Gy, SE 0.3 Gy), and heterogeneity corrected plans range from
47.9 Gy to 68.6 Gy (mean 58.9 Gy, SE 1.1 Gy). The per-patient difference ranges from -14.2
Gy to 1.8 Gy (mean -3.8 Gy, SE 1.0 Gy, p=0.001).
Conformality of PTV coverage:
The RTOG 0236 protocol forces conformality of PTV coverage by limiting the ratio of the
volume of the prescription isodose to the volume of the PTV. The requirement is that this ratio
must be equal to or less than 1.4 when the dose calculation assumes unit density for all
tissues (see Table 1). Under these conditions, the calculated ratio for the 20 cases has a

minimum value of 0.9 and maximum value of 1.7 (mean 1.2, SE 0.045), with only 2 cases
violating the limit of 1.4. With the heterogeneity correction applied, the isodose volume for the
prescription dose decreased. In this case the minimum ratio was 0.6 and the maximum ratio
was 1.5 (mean 1.0, SE 0.045). Only 1 case violates the upper limit of 1.4.
Maximum dose to any point 2 cm or greater away from the PTV in any direction (D2cm) varied
between 20.7 Gy as a minimum value to 49.1 Gy as a maximum (mean 35.2 Gy, SE 1.7 Gy)
for unit density calculation. This parameter ranged from 20.3 Gy to 56.0 Gy (mean 38.5, SE
2.2 Gy) with heterogeneity corrections. The per-patient difference ranged from -1.1 Gy to 8.2
Gy (mean 3.3 Gy, SE 0.6 Gy, p<0.0001). These numbers indicate, unlike the isodose line for
the prescription dose, the shift of the lower value isodose lines is away from the isocenter as
shown in Figure 3. Since future SBRT lung protocols will be designed to use heterogeneity
corrected treatment planning, it is important to modify the dose constraints stated in the RTOG
0236 protocol to better reflect the actual delivered doses. This modification is included in Table
1 under the heading “Hetero.” Notice that the ratio of the 60 Gy isodose volume to the total
PTV volume has not been changed. The maximum dose at 2 cm distance from the PTV has
been modified. The numbers given in the table are the values that trigger a major deviation for
the submitted case.

The comparison between non-corrected and heterogeneity corrected

maximum doses at 2 cm from the PTV is shown in the table. It can be seen that the D2cm
values as stated in the 0236 protocol for the unit density treatment plans are consistently lower
than the D2cm values for the heterogeneity corrected plans.
Another measure of the dose distribution comformality used in the RTOG 0236 protocol is the
volume of the isodose surface for the dose that is 50% of the prescription dose value. For the
50% isodose spillage, the protocol requires that the ratio of the volume within an isodose

surface for 50% of the prescription dose (30 Gy for homogeneous calculation and 56 Gy for
heterogeneity corrected calculations) to the volume of the PTV (R50%) must be no greater than
the R50% value specified in Table 1. The R50% values in this table were determined based on
unit density dose calculation and are dependent upon PTV volume. It is interesting to compare
the R50% values for the plans based on unit density calculations to the plans with heterogeneity
correction applied. The R50% value for the unit density plans have a minimum value of 2.9, and
a maximum of 6.3 (mean 3.8, SE 0.2) as compared to a minimum of 3.2 and a maximum of 6.5
(mean 4.3, SE 0.2) for the plans with heterogeneity corrections. The ratio between the
R50%value over its corresponding criterion increases from 1.0 ± 0.2 (minimum 0.7, maximum
1.5) to 1.1 ± 0.2 (minimum 0.8, maximum 1.6). The percent pass rate (ratio <=1.0) decreases
from 70% to 35%.
Critical structures:
For the critical structures, the percent lung volume receiving 20 Gy or more (V20) is limited to
be not more than 10% per the protocol, with no deviation defined as < 10% and a minor
deviation defined at 10-15%(Table 1). Due to the relatively small size and location of the target
volumes from the submitted cases, this criterion is met by almost all cases with a large margin
(mean 5.5%, SE 0.6%, range = 2.5% – 12.7%). With changes from the heterogeneity
correction, percent lung volume receiving 20 Gy is still well under the required upper limit of
10% (mean 5.9%, SE 0.6%, range = 2.5% – 14.1%). One case that doesn’t meet the criterion
before correction (12.7%) still deviates from the limit after correction (14.1%). The per-patient
difference with heterogeneity corrections ranges from -0.1% - 1.4% (mean 0.3%, SE 0.1%, p =
0.0003).

The absolute maximum dose limits for other critical structures are listed in Table 2. Without
heterogeneity corrections, the dose to the spinal cord ranges from 0.4 Gy to 18.5 Gy (mean
9.9 Gy, SE 1.3 Gy). With heterogeneity correction, the range is 0.3 Gy to 22.0 Gy (mean 10.9
Gy, SE 1.4 Gy). The per-patient difference ranges from -0.3 Gy to 3.7 Gy (mean 0.9 Gy, SE
0.3 Gy, p = 0.006). One case with maximum dose to the spinal cord greater than the 18 Gy
limit (18.5 Gy) before correction increases its value to 22 Gy after correction. Due to the fact
that the submitted cases all have target volumes distal from the mediastinum, the doses to
esophagus, heart and the other critical structures listed in Table 2 are negligible. However, one
out of twenty cases has esophagus receiving a maximum dose of 6.1 Gy without heterogeneity
correction, which increases to 12.0 Gy with the correction. Two out of the twenty cases having
esophagus maximum doses of 0.0 Gy without correction see an increase of maximum
esophagus doses to 0.3 Gy and 11.9 Gy respectively after the correction, showing potentially
substantial dose increase to nearby critical structures with heterogeneity correction.
Suggested

prescribed

dose

and

constraint

adjustments

for

protocols

with

heterogeneity correction:
Based on the results presented above for 20 cases submitted for the RTOG 0236 protocol,
there is a need to adjust prescribed dose and constraints that control conformality for future
protocols that use heterogeneity corrections. It is recommended here that future protocols that
are patterned after the RTOG 0236 protocol in terms of total prescribed dose and dose
fractionation use a prescribed dose of 56 Gy instead of the 60 Gy used for homogeneous
tissue density calculations. Suggested values for adjusted constraints are listed in Table 1
under the column “hetero”. These values are obtained so that approximately 80% of the

submitted cases meet the criteria with heterogeneity correction, since re-optimization of beam
weights are not performed for these heterogeneity corrected plans.
Because of the characteristics of the target volumes, which are distal from the mediastinum for
the submitted cases, the percentage of cases meeting the criteria to cord, esophagus, heart
and the other critical structures listed in Table 2 is not affected by turning on the heterogeneity
correction. No changes are recommended for the values in Table 2 with heterogeneity
correction for similar cases.
Conclusions:
Significant differences are found between the calculated doses submitted to meet the
requirements of RTOG 0236 and the actual heterogeneity corrected doses. These results are
similar to the single-institutional findings of reference 20.

The volume of PTV receiving

prescription dose decreases over 10% on average. Dose to 95% of the PTV volume
decreased on average by 4.7 Gy. Dose spilling to normal tissues noticeably increased in only
a limited number of patients with heterogeneity corrections applied. However, in a few of these
cases, the increases were marked and exceeded the protocol specified constraints. The
design of the RTOG 0236 protocol was patterned on pilot studies that did not use tissue
heterogeneity corrections for the treatment planning. The information provided in the current
study will be used for designing future RTOG protocols to better match the true dose delivered
for RTOG 0236.

Adjusting the dose for future studies is extremely important given the

hypofractionated dose schedule and reduced margins used for RTOG 0236.
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Table 1. Dosimetric criteria for target coverage, “Homo” are for unit density and “Hetero” are
suggested adjustments to be used when heterogeneity correction are applied.

Maximum
PTV
Dimension
(cm)

2
2.5
3
3.5
4
4.5
5
5.5
6
6.5
7

Ratio of
Prescription
Isodose
Volume
to the PTV

Ratio of 50% Maximum Dose Percent of Lung PTV
Prescription
2 cm from PTV receiving 20 Gy Volume
Isodose
in any Direction, total or more, (cc)
Volume
D2cm
V20 (%)
to the PTV, % of Prescription
R50%
Dose

Major
Major
Major
Deviation
Deviation
Deviation
Homo Hetero Homo Hetero Homo Hetero
60 Gy 56 Gy
>1.4
>4.1
>7.0
>50.2 >55.2
>1.4
>4.1
>5.8
>50.2 >55.2
>1.4
>4.1
>5.4
>50.2 >55.2
>1.4
>4.1
>5.3
>50.2 >55.2
>1.4
>4.0
>5.2
>54.0 >59.7
>1.4
>3.9
>5.0
>57.8 >62.8
>1.4
>3.8
>4.8
>61.8 >75.2
>1.4
>3.7
>4.5
>69.5 >83.8
>1.4
>3.5
>4.1
>69.5 >86.8
>1.4
>3.3
>3.7
>73.3 >88.7
>1.4
>3.1
>3.5
>77.2 >90.7

Major
Deviation

>15
>15
>15
>15
>15
>15
>15
>15
>15
>15
>15

1.8
3.8
7.4
13.2
21.9
33.8
49.6
69.9
95.1
125.8
162.6

Table 2. Dose limits for critical structures
Organ

Volume

Dose (cGy)

Spinal Cord

Any point

18 Gy

Esophagus

Any point

27 Gy

Ipsilateral Brachial Plexus

Any point

24 Gy

Heart

Any point

30 Gy

Trachea and Ipsilateral Bronchus

Any point

30 Gy
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Figure 1 The non-coplanar beam arrangement for the 3D conformal planning of the
stereotactic radiation treatment (PTV and cord are shown in solid, orientation icon labels:
H:head, R:Right, L:Left).
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Figure 2 - PTV volume distribution and the number of beams (given above each bar) employed
for the radiotherapy treatment plan.

Figure 3 Isodose distributions for with unit density (left) and with density corrections (right). The
dashed lines are PTV (inside) and 2 cm from PTV (outside). The solid lines are for 60 Gy
isodose (inside) and 30 Gy isodose (outside).
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Figure 4 Dose volume histograms for PTV coverage with unit density and with density
correction, for the case shown in Figure 3, one of the cases with larger than average
differences between heterogeneity corrected and unit density plans chosen for illustration.
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Figure 5 Doses at isocenter point for all the plans with and without heterogeneity correction.

10
5
0
Percent Volume Coverage

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

-5
-10
-15
-20

V60 Hetero Off- 95%

-25

V60 Hetero On - 95%

-30
-35
-40

Cases

Figure 6 Percent volume that receives prescription dose 60 Gy or higher, as compared against
the protocol required value of 95%, without and with heterogeneity correction.
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Figure 7 Percent volume that receives 90% of prescription dose: 54 Gy or higher, as compared
against the protocol required value of 99%, without and with heterogeneity correction.
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